Key result
A genome-wide polygenic risk score successfully stratified individuals for hypertension risk, with those in the highest decile having a 3.62-fold increased odds of hypertension compared to the median decile.
Why the study?
Genome-wide association studies show an underlying polygenic architecture in hypertension, but the polygenic and pathway-specific components of primary hypertension needed dissection.
Does a pathway-specific polygenic risk score associate with primary hypertension status in European cohorts?
Case-Control (n=3,536)
Yes
Does a pathway-specific polygenic risk score associate with primary hypertension status in European cohorts?
Odds Ratio: 3.62 (95% CI 2.01–6.32)
p-value: p=9.01E-07
Pathway-specific polygenic risk scores identify the calcium signaling pathway as a significant genetic contributor to primary hypertension, highlighting potential pharmacological targets.
Supports genetic risk stratification for hypertension; leaves open clinical utility and pathway-specific targeting.
INTRODUCTION AND OBJECTIVES: Genome-wide association studies have identified a high number of genetic loci associated with hypertension suggesting the presence of an underlying polygenic architecture. In this study, we aimed to dissect the polygenic component of primary hypertension searching also for pathway-specific components. METHODS: The polygenic risk score (PRS) models, based on the UK biobank genetic signals for hypertension status, were obtained on a target Italian case/control cohort including 561 cases and 731 hyper-normal controls from HYPERGENES, and were then applied to an independent validation cohort composed by multi-countries European-based samples including 1,284 cases and 960 hyper-normal controls. RESULTS: = 6.47E-08) in the target and validation cohorts, respectively. The relatively high case/control ORs across PRS quantiles corroborates the presence of strong polygenic components which could be driven by an enrichment of risk alleles within the cases but also by potential enrichment of protective alleles in the old normotensive controls. Moreover, novel pathway-specific PRS revealed an enrichment of the polygenic signal attributable to specific biological pathways. Among those the most significantly associated with hypertension status was the calcium signaling pathway together with other mainly related such as the phosphatidylinositol/inositol phosphate pathways. CONCLUSIONS: The development of pathway-specific PRS could prioritize biological mechanisms, according to their contribution to the genetic susceptibility, whose regulations might be a potential pharmacological preventive target.
No takes yet. Share an insight, caveat, or question.
Maj et al. (2022) conducted a case-control in Primary hypertension (n=3,536). High polygenic risk score (highest decile) vs. Median polygenic risk score decile was evaluated on Hypertension status (highest vs median PRS decile in target cohort) (OR 3.62, 95% CI 2.01-6.32, p=9.01E-07). A genome-wide polygenic risk score successfully stratified individuals for hypertension risk, with those in the highest decile having a 3.62-fold increased odds of hypertension compared to the median decile.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: